ID: ALA3735648

Max Phase: Preclinical

Molecular Formula: C30H33N3O2

Molecular Weight: 467.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1(C)c2cc(C3CCN(CC4CCOCC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21

Standard InChI:  InChI=1S/C30H33N3O2/c1-30(2)25-16-22(21-7-11-33(12-8-21)18-19-9-13-35-14-10-19)4-6-23(25)28(34)27-24-5-3-20(17-31)15-26(24)32-29(27)30/h3-6,15-16,19,21,32H,7-14,18H2,1-2H3

Standard InChI Key:  VWCZORWQNKCYGE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 467.61

Molecular Weight (Monoisotopic): 467.2573

AlogP: 5.52

#Rotatable Bonds: 3

Polar Surface Area: 69.12

Molecular Species: BASE

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.17

CX Basic pKa: 9.30

CX LogP: 4.92

CX LogD: 3.03

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.55

Np Likeness Score: -0.20

References

1. Jiang X, Zhou J, Ai J, Song Z, Peng X, Xing L, Xi Y, Guo J, Yao Q, Ding J, Geng M, Zhang A..  (2015)  Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.,  105  [PMID:26476749] [10.1016/j.ejmech.2015.10.005]

2. Song Z, Xia Z, Ji Y, Xing L, Gao Y, Ai J, Geng M, Zhang A..  (2016)  An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.,  118  [PMID:27131066] [10.1016/j.ejmech.2016.04.046]

3. Han M, Wang C, Ji Y, Song Z, Xing L, Su Y, Wang X, Zhang A, Ai J, Geng M..  (2016)  Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.,  26  (22): [PMID:27769623] [10.1016/j.bmcl.2016.10.039]

Source

Source(1):

• Scientific Literature